PROJECT

Projects

Summary of Proposed Investment

Project Number

28199

Company Name

GRANULES INDIA LIMITED

Date SPI Disclosed

Apr 13, 2009

Country

India

Industry

Health, Education and Life Sciences

Projected Board Date

May 20, 2009

Status

Completed

Sector

Pharmaceuticals and Medicine

Department

Gbl Ind, Manufact, Agribus & Services

Environmental Category

C - No Impact

Previous Events

Approved : Jul 23, 2007
Signed : May 29, 2009
Invested : Jul 29, 2011

Project Description

Granules India Limited (“Granules”) is a leading Contract Manufacturing Organization (“CMO”) supplying high volume Active Pharmaceutical Ingredients (“APIs”) and Pharmaceutical Formulation Intermediates (“PFIs”) to the bulk over-the-counter (“OTC”) drugs industry in the U.S., Europe, Latin America, Australia and India. Paracetamol (used in Tylenol and Panadol brand names in the U.S. and Europe, respectively) and ibuprofen (Advil and Motrin) are the company’s main products, but it also supplies the industry with guaifenesin (ultimately used in cough medications) and metformin (anti-diabetes drug ingredient).

The company has four production units in three locations in the vicinity of Hyderabad, in south India. Granules management and IFC’s industry specialist have identified a number of energy and water efficiency projects, including solvent recovery as well as cleaner production improvements at the company’s Jeedimetla API facility, which will have beneficial environmental impacts (together, the “Cleaner Production project”). For example, the company will recover more of the steam and condensate used in production and recycle them, thereby reducing its energy and water intake. Variable Frequency Drives (“VFDs”) and appropriate scaling of certain motors and cooling towers will further contribute to the company’s energy efficiency and bottom line.

Sponsor / Cost / Location

Development Impact